1. Home
  2. IDYA vs LMAT Comparison

IDYA vs LMAT Comparison

Compare IDYA & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • LMAT
  • Stock Information
  • Founded
  • IDYA 2015
  • LMAT 1983
  • Country
  • IDYA United States
  • LMAT United States
  • Employees
  • IDYA N/A
  • LMAT N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • LMAT Medical/Dental Instruments
  • Sector
  • IDYA Health Care
  • LMAT Health Care
  • Exchange
  • IDYA Nasdaq
  • LMAT Nasdaq
  • Market Cap
  • IDYA 2.2B
  • LMAT 1.9B
  • IPO Year
  • IDYA 2019
  • LMAT 2006
  • Fundamental
  • Price
  • IDYA $24.27
  • LMAT $95.72
  • Analyst Decision
  • IDYA Strong Buy
  • LMAT Buy
  • Analyst Count
  • IDYA 13
  • LMAT 6
  • Target Price
  • IDYA $51.36
  • LMAT $99.67
  • AVG Volume (30 Days)
  • IDYA 1.1M
  • LMAT 161.2K
  • Earning Date
  • IDYA 08-05-2025
  • LMAT 08-05-2025
  • Dividend Yield
  • IDYA N/A
  • LMAT 0.84%
  • EPS Growth
  • IDYA N/A
  • LMAT 22.69
  • EPS
  • IDYA N/A
  • LMAT 2.05
  • Revenue
  • IDYA $7,000,000.00
  • LMAT $234,639,000.00
  • Revenue This Year
  • IDYA $101.44
  • LMAT $13.88
  • Revenue Next Year
  • IDYA $263.37
  • LMAT $8.81
  • P/E Ratio
  • IDYA N/A
  • LMAT $46.59
  • Revenue Growth
  • IDYA N/A
  • LMAT 14.11
  • 52 Week Low
  • IDYA $13.45
  • LMAT $71.42
  • 52 Week High
  • IDYA $40.74
  • LMAT $109.58
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 52.57
  • LMAT 72.83
  • Support Level
  • IDYA $22.09
  • LMAT $90.93
  • Resistance Level
  • IDYA $24.75
  • LMAT $96.12
  • Average True Range (ATR)
  • IDYA 1.25
  • LMAT 2.52
  • MACD
  • IDYA -0.13
  • LMAT 1.23
  • Stochastic Oscillator
  • IDYA 40.05
  • LMAT 88.78

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

Share on Social Networks: